Early results from coronavirus drug are promising, but more rigorous testing needed

• A potential coronavirus drug called Remdesivir showed encouraging results in a preliminary study.
• Remdesivir is an existing drug from Gilead that was initially designed to help Ebola patients.
• The number of coronavirus cases in the United States recently surpassed 500,000.
• Visit BGR's homepage for more stories.

Despite some indications that the coronavirus may have peaked in some U.S. areas, the pandemic is still ravaging many areas across the country. Just this past week, for instance, New York City -- which has been categorized as the epicenter of the virus in the United States -- saw its highest single-day death toll from the coronavirus. All told, new data from the John Hopkins Coronavirus Resources Center indicates that the cumulative number of coronavirus cases in the U.S. now exceeds 500,000. Meanwhile, the total number of coronavirus-related deaths in the U.S. recently reached 20,000 and surpassed Italy in the process.

All the while, researchers are still working furiously to come up with coronavirus vaccines and drugs. One of the more promising treatments centers on Remdesivir, an existing drug from Gilead that was initially designed to treat Ebola patients.

Continue reading...

Today's Top Deals

1. 10 deals you don’t want to miss on Saturday: AirPods Pro, $5 wireless charger, $20 AirPods rivals, Echo blowout, more
2. Today’s top deals: Rare AirPods Pro sale, Anker blowout, DIY face masks, Fire TV Stick 4K for $25, smart plugs for $6, more
3. Today’s best deals: Huge Echo speaker blowout, $11 waterproof speaker, $20 headphones, DIY face mask supplies, more

Trending Right Now:

1. Coronavirus spreads through the air outside with shocking ease, study says
2. First ‘Avengers 5’ details might’ve just leaked
3. IRS launches online tool to speed up your coronavirus stimulus check

Early results from coronavirus drug are promising, but more rigorous testing needed originally appeared on BGR.com on Sat, 11 Apr 2020 at 15:30:31 EDT. Please see our terms for use of feeds.